# Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.

> **NCT00341328** · PHASE3 · COMPLETED · sponsor: **Ministry of Science and Technology, India** · enrollment: 300 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** Intradermal injection of Mycobacterium w

## Key facts

- **NCT ID:** NCT00341328
- **Lead sponsor:** Ministry of Science and Technology, India
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2011-10
- **Final completion:** 2012-03
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2013-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00341328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00341328, "Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00341328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*